Japan's in vitro diagnostics (IVD) market was valued at approximately $4.22 billion as of 2025 and is expected to grow to approximately $7.70 billion by 2035. An analysis reports that population aging, the rising prevalence of chronic diseases, advances in personalized medicine and the expansion of AI-integrated testing will support growth.
Japan's in vitro diagnostics (IVD) market was estimated at approximately $4.22 billion as of 2025 and is forecast to expand at a CAGR of 6.2% from 2026 to 2035, reaching approximately $7.70 billion by 2035. Key growth drivers include rising demand for diagnosis associated with population aging, the growing burden of chronic and infectious diseases, advances in personalized medicine, the growing adoption of molecular diagnostics, and the expansion of AI-integrated, at-home and point-of-care testing.
IVD comprises tests that analyze specimens such as blood, urine and tissue outside the body. In Japan, the increasing need for long-term management of diabetes, cancer, cardiovascular disease and kidney disease is raising the importance of early diagnosis and regular testing.
Advances in infectious disease diagnostic technologies and the use of new molecular markers in cancer diagnosis are supporting market growth. Approvals of new diagnostic reagents and instruments are increasing the market's value-added profile, while the adoption of molecular diagnostics, AI analysis, and point-of-care and at-home testing is expected to reshape the market structure.
Key competitors include Roche, Bio-Rad, bioMérieux and Abbott, while companies such as Sysmex, Thermo Fisher, QIAGEN, Quidel and Danaher are also positioned as major players.
Key themes through 2035 are expected to center on infectious disease diagnostics, molecular diagnostics, PCR, early cancer diagnosis, AMR countermeasures, personalized medicine, point-of-care and at-home diagnostics, and AI-integrated testing. Japan's IVD market is expected to develop from one centered on central laboratories into a distributed and precision diagnostics market.